Evidence map›Paper›PMID 41251194›Full record

ArticleJournal of medical virology2025

Co-Infection With Hepatitis E Virus and SARS-CoV-2 in a Lymphoma Patient.

Yacine Boucetta, Céline Boschi, Erika Peroni, Rodolphe Jean, Erwan Bories, Patrick Borentain, Julien Andreani, Philippe Colson

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yacine BoucettaIHU Méditerranée Infection, Marseille, France.
Céline BoschiIHU Méditerranée Infection, Marseille, France.
Erika PeroniIHU Méditerranée Infection, Marseille, France.
Rodolphe JeanAssistance Publique-Hôpitaux de Marseille (AP-HM), Internal Medicine and Clinical Immunology Department, CHU Conception, Marseille, France.
Erwan BoriesPrivate medical practice in hepatogastroenterology, Aix-en-Provence, France.
Patrick BorentainAssistance Publique-Hôpitaux de Marseille (AP-HM), Hôpital Timone, service d'Hépatologie, Marseille, France.
Julien AndreaniIHU Méditerranée Infection, Marseille, France.
Philippe ColsonIHU Méditerranée Infection, Marseille, France.

Funding

This workstudy was supported by the French Government under the "Investments for the Future" program managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU-03; and by the French Ministry of Higher Education, Research and Innovation (Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation) and the French Ministry of Solidarity and Health (Ministère des Solidarités et de la Santé).
6 · The paper itself

Abstract

Hepatitis E virus (HEV) and SARS-CoV-2 are both ubiquitous worldwide. We report here a rare case of HEV and SARS-CoV-2 coinfection. HEV and SARS-CoV-2 diagnoses were carried out by qPCR. Virus genotyping was performed by analyzing partial or near full-length genomes obtained by next-generation sequencing from plasma or nasopharyngeal specimens, respectively. The case was a lymphoma patient admitted to hospital for oxygen-requiring qPCR-documented Covid-19. SARS-CoV-2 was a Delta variant. Reevaluation of a liver cytolysis documented 1 year earlier revealed concurrent chronic hepatitis E at cirrhosis stage. HEV genotype was 3c. Ribavirin was administered, but to date only temporarily led to HEV RNA undetectability in plasma when combined with immunosuppressive therapy interruption. This case and the three previous cases of coinfection with HEV and SARS-CoV-2 point out the possible deleterious effect of SARS-CoV-2 on the liver and the increased risk of such concurrent infections in immunocompromized patients.

Indexed as

CoinfectionCOVID-19Hepatitis ELymphomaSARS-CoV-2Antiviral AgentsHepatitis E virusHumansImmunocompromised HostRibavirinRNA, ViralAntiviral AgentsRibavirinRNA, Viralcoinfectionhepatitishepatitis E virusSARS‐CoV‐2

Identifiers

PMID41251194
PMCPMC12624820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.